{"transactions":[{"id":4635459,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":35891,"kind":"person","name":"REICIN ALISE","position":1,"cik":"0001757533","reported_name":"REICIN ALISE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-03T00:57:58.000Z","date":"2026-09-25","kind":"tax_withholding","planned":false,"acquired":false,"shares":1545,"price":23.67,"value":36570.15,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units granted on September 25, 2025."}],"balance_after":309078,"source":{"system":"sec-edgar","filing":"0001757533-26-000016","document":"form4-10022026_081054.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681087/000175753326000016/form4-10022026_081054.xml","form_type":"4"}},{"id":3531855,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":35891,"kind":"person","name":"REICIN ALISE","position":1,"cik":"0001757533","reported_name":"REICIN ALISE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-09-08T20:45:05.000Z","date":"2026-09-03","kind":"grant","planned":false,"acquired":true,"shares":69250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/8th of the shares subject to the option vest on September 3, 2026 with the remaining shares subject to the option vesting in the following 42 equal monthly installments beginning on October 3, 2026, subject to the Reporting Person's continued service to the Issuer on each such vesting date."}],"balance_after":69250,"derivative":{"exercise_price":29.92,"expiration_date":"2036-09-02","underlying":"Common Stock","underlying_shares":69250},"source":{"system":"sec-edgar","filing":"0001757533-26-000014","document":"form4-09082026_040901.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1757533/000175753326000014/form4-09082026_040901.xml","form_type":"4"}},{"id":728569,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":35891,"kind":"person","name":"REICIN ALISE","position":1,"cik":"0001757533","reported_name":"REICIN ALISE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-23T21:52:01.000Z","date":"2026-06-20","kind":"tax_withholding","planned":false,"acquired":false,"shares":924,"price":30.34,"value":28034.16,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units granted on December 4, 2024."}],"balance_after":310623,"source":{"system":"sec-edgar","filing":"0001757533-26-000012","document":"form4-06232026_090656.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681087/000175753326000012/form4-06232026_090656.xml","form_type":"4"}},{"id":732918,"issuer":{"id":4718,"kind":"organization","name":"Immatics N.V."},"owners":[{"id":35891,"kind":"person","name":"REICIN ALISE","position":1,"cik":"0001757533","reported_name":"REICIN ALISE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-18T20:49:37.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":48000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These Options vest 100% on the first anniversary of the grant date, June 16, 2026."}],"balance_after":48000,"derivative":{"exercise_price":9.09,"expiration_date":"2036-06-15","underlying":"Ordinary Shares","underlying_shares":48000},"source":{"system":"sec-edgar","filing":"0000950103-26-009244","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1809196/000095010326009244/ownership.xml","form_type":"4"}},{"id":747417,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":35891,"kind":"person","name":"REICIN ALISE","position":1,"cik":"0001757533","reported_name":"REICIN ALISE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-05T20:38:16.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. (\"Sana\"), provided that the reporting person provides continuous service to Sana through such date."}],"balance_after":90000,"derivative":{"exercise_price":2.96,"expiration_date":"2036-06-03","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001757533-26-000011","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1757533/000175753326000011/primarydocument.xml","form_type":"4"}},{"id":857738,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":35891,"kind":"person","name":"REICIN ALISE","position":1,"cik":"0001757533","reported_name":"REICIN ALISE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-03-05T22:47:24.000Z","date":"2026-03-04","kind":"grant","planned":false,"acquired":true,"shares":69250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the option vest in 48 equal monthly installments beginning on April 4, 2026, subject to the Reporting Person's continued service to the Issuer on each such vesting date."}],"balance_after":69250,"derivative":{"exercise_price":27.41,"expiration_date":"2036-03-03","underlying":"Common Stock","underlying_shares":69250},"source":{"system":"sec-edgar","filing":"0001757533-26-000009","document":"form4-03052026_100320.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1681087/000175753326000009/form4-03052026_100320.xml","form_type":"4"}},{"id":857737,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":35891,"kind":"person","name":"REICIN ALISE","position":1,"cik":"0001757533","reported_name":"REICIN ALISE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-05T22:47:24.000Z","date":"2026-03-04","kind":"grant","planned":false,"acquired":true,"shares":76500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The shares shall vest in 3 equal annual installments on each of March 4, 2027, March 4, 2028 and March 4, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date."}],"balance_after":311547,"source":{"system":"sec-edgar","filing":"0001757533-26-000009","document":"form4-03052026_100320.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681087/000175753326000009/form4-03052026_100320.xml","form_type":"4"}},{"id":857736,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":35891,"kind":"person","name":"REICIN ALISE","position":1,"cik":"0001757533","reported_name":"REICIN ALISE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-05T21:30:32.000Z","date":"2026-02-11","kind":"purchase","planned":false,"acquired":true,"shares":2500,"price":21.1,"value":52750.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $21.02 to $21.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by the Reicin-Boiarsky Family Trust (the \"Trust\"). The Reporting Person's spouse is a co-trustee of the Trust. Accordingly, the Reporting Person may be deemed to have shared voting and dispositive power over the securities held by the Trust. The Reporting Person disclaims beneficial ownership of the shares held by the Trust except to the extent of her pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose."}],"balance_after":127030,"source":{"system":"sec-edgar","filing":"0001757533-26-000008","document":"form4a-03052026_040323.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681087/000175753326000008/form4a-03052026_040323.xml","form_type":"4/A","original_submission_date":"2026-02-12"}},{"id":907098,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":35891,"kind":"person","name":"REICIN ALISE","position":1,"cik":"0001757533","reported_name":"REICIN ALISE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-12T21:15:09.000Z","date":"2026-02-11","kind":"purchase","planned":false,"acquired":true,"shares":2500,"price":21.1,"value":52750.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $21.02 to $21.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":237547,"source":{"system":"sec-edgar","filing":"0001757533-26-000005","document":"form4-02122026_040204.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681087/000175753326000005/form4-02122026_040204.xml","form_type":"4"}},{"id":911362,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":35891,"kind":"person","name":"REICIN ALISE","position":1,"cik":"0001757533","reported_name":"REICIN ALISE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-10T21:07:58.000Z","date":"2026-02-04","kind":"tax_withholding","planned":false,"acquired":false,"shares":4104,"price":23.22,"value":95294.88,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units granted on February 4, 2025."}],"balance_after":235047,"source":{"system":"sec-edgar","filing":"0001757533-26-000004","document":"form4-02102026_090253.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681087/000175753326000004/form4-02102026_090253.xml","form_type":"4"}},{"id":949888,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":35891,"kind":"person","name":"REICIN ALISE","position":1,"cik":"0001757533","reported_name":"REICIN ALISE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-01-05T22:02:32.000Z","date":"2025-12-31","kind":"exercise","planned":false,"acquired":false,"shares":10966,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Received in exchange for a stock option to acquire 63,478 shares of common stock pursuant to that certain merger, as more fully described on the Reporting Person's Form 4 filed with the Securities and Exchange Commission on June 24, 2024. https://www.sec.gov/Archives/edgar/data/1681087/000141588924017952/xslF345X05/form4-06242024_080648.xml"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option vested as follows: (i) 4,079 shares on June 30, 2024; (ii) 4,078 shares on July 31, 2024, (iii) 4,078 shares on August 31, 2024, (iv) 4,079 shares on September 30, 2024, (v) 4,078 shares on October 31, 2024, (vi) 1,297 shares on November 30, 2024, (vii) 4,078 shares on January 31, 2025, (viii) 4,078 shares on February 28, 2025 and (iv) 4,078 shares on March 31, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date.."}],"balance_after":22957,"derivative":{"exercise_price":2.38,"expiration_date":"2031-06-27","underlying":"Common Stock","underlying_shares":10966},"source":{"system":"sec-edgar","filing":"0001757533-26-000002","document":"form4-01052026_100128.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1681087/000175753326000002/form4-01052026_100128.xml","form_type":"4"}},{"id":949887,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":35891,"kind":"person","name":"REICIN ALISE","position":1,"cik":"0001757533","reported_name":"REICIN ALISE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-05T22:02:32.000Z","date":"2025-12-31","kind":"exercise","planned":false,"acquired":true,"shares":10966,"price":2.38,"value":26099.08,"ownership":{"direct":true},"balance_after":239151,"source":{"system":"sec-edgar","filing":"0001757533-26-000002","document":"form4-01052026_100128.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681087/000175753326000002/form4-01052026_100128.xml","form_type":"4"}},{"id":1031071,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":35891,"kind":"person","name":"REICIN ALISE","position":1,"cik":"0001757533","reported_name":"REICIN ALISE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-09-29T21:00:05.000Z","date":"2025-09-25","kind":"grant","planned":false,"acquired":true,"shares":26710,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the option vest in 48 equal monthly installments beginning on October 25, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date."}],"balance_after":26710,"derivative":{"exercise_price":14.71,"expiration_date":"2035-09-24","underlying":"Common Stock","underlying_shares":26710},"source":{"system":"sec-edgar","filing":"0001757533-25-000004","document":"form4-09292025_050901.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1681087/000175753325000004/form4-09292025_050901.xml","form_type":"4"}},{"id":1031070,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":35891,"kind":"person","name":"REICIN ALISE","position":1,"cik":"0001757533","reported_name":"REICIN ALISE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-09-29T21:00:05.000Z","date":"2025-09-25","kind":"grant","planned":false,"acquired":true,"shares":14700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The shares shall vest in 3 equal annual installments on each of September 25, 2026, September 25, 2027 and September 25, 2028, subject to the Reporting Person's continued service to the Issuer on each such vesting date."}],"balance_after":228185,"source":{"system":"sec-edgar","filing":"0001757533-25-000004","document":"form4-09292025_050901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681087/000175753325000004/form4-09292025_050901.xml","form_type":"4"}},{"id":1102335,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":35891,"kind":"person","name":"REICIN ALISE","position":1,"cik":"0001757533","reported_name":"REICIN ALISE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-06-24T20:55:39.000Z","date":"2025-06-20","kind":"tax_withholding","planned":false,"acquired":false,"shares":859,"price":19.81,"value":17016.79,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the non-reportable vesting and settlement of restricted stock units granted on December 4, 2024."}],"balance_after":213485,"source":{"system":"sec-edgar","filing":"0001415889-25-018106","document":"form4-06242025_080636.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681087/000141588925018106/form4-06242025_080636.xml","form_type":"4"}},{"id":1117318,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":35891,"kind":"person","name":"REICIN ALISE","position":1,"cik":"0001757533","reported_name":"REICIN ALISE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-09T20:39:32.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 5, 2026 and (ii) immediately prior to the 2026 annual meeting of stockholders of Sana Biotechnology, Inc. (\"Sana\"), provided that the reporting person provides continuous service to Sana through such date."}],"balance_after":80000,"derivative":{"exercise_price":2.55,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001562180-25-004643","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1757533/000156218025004643/primarydocument.xml","form_type":"4"}},{"id":1279993,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":35891,"kind":"person","name":"REICIN ALISE","position":1,"cik":"0001757533","reported_name":"REICIN ALISE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-02-06T21:05:06.000Z","date":"2025-02-04","kind":"grant","planned":false,"acquired":true,"shares":101953,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the option vest in 48 equal monthly installments beginning on March 4, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date."}],"balance_after":101953,"derivative":{"exercise_price":48.01,"expiration_date":"2035-02-03","underlying":"Common Stock","underlying_shares":101953},"source":{"system":"sec-edgar","filing":"0001415889-25-003225","document":"form4-02062025_040201.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1681087/000141588925003225/form4-02062025_040201.xml","form_type":"4"}},{"id":1279992,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":35891,"kind":"person","name":"REICIN ALISE","position":1,"cik":"0001757533","reported_name":"REICIN ALISE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-02-06T21:05:06.000Z","date":"2025-02-04","kind":"grant","planned":false,"acquired":true,"shares":36047,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The shares shall vest in 3 equal annual installments on each of February 4, 2026, February 4, 2027 and February 4, 2028, subject to the Reporting Person's continued service to the Issuer on each such vesting date."}],"balance_after":214344,"source":{"system":"sec-edgar","filing":"0001415889-25-003225","document":"form4-02062025_040201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681087/000141588925003225/form4-02062025_040201.xml","form_type":"4"}},{"id":1340085,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":35891,"kind":"person","name":"REICIN ALISE","position":1,"cik":"0001757533","reported_name":"REICIN ALISE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2024-12-06T22:19:48.000Z","date":"2024-12-04","kind":"grant","planned":false,"acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to the option vest as to 25% of the shares on June 20, 2025 with the remainder vesting in the following 36 equal monthly installments, subject to the Reporting Person's continued service to the Issuer on each such vesting date."}],"balance_after":6000,"derivative":{"exercise_price":51.28,"expiration_date":"2034-12-03","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001415889-24-028516","document":"form4-12062024_101244.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1681087/000141588924028516/form4-12062024_101244.xml","form_type":"4"}},{"id":1340084,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":35891,"kind":"person","name":"REICIN ALISE","position":1,"cik":"0001757533","reported_name":"REICIN ALISE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-12-06T22:19:48.000Z","date":"2024-12-04","kind":"grant","planned":false,"acquired":true,"shares":11717,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The shares shall vest in 4 equal annual installments with the first installment vesting on June 20, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"4,079 of these shares are subject to vesting and a repurchase right in favor of the Issuer. Such repurchase right will lapse on December 31, 2024 so long as the Reporting Person continues to provide service to the Issuer on such vesting date."}],"balance_after":178297,"source":{"system":"sec-edgar","filing":"0001415889-24-028516","document":"form4-12062024_101244.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681087/000141588924028516/form4-12062024_101244.xml","form_type":"4"}},{"id":1454388,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":35891,"kind":"person","name":"REICIN ALISE","position":1,"cik":"0001757533","reported_name":"REICIN ALISE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-15T20:11:56.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2025 and (ii) immediately prior to the 2025 annual meeting of stockholders of Sana Biotechnology, Inc. (\"Sana\"), provided that the reporting person provides continuous service to Sana through such date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired."}],"balance_after":65000,"derivative":{"exercise_price":7.36,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001562180-24-005719","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1757533/000156218024005719/primarydocument.xml","form_type":"4/A","original_submission_date":"2024-06-07"}},{"id":1470281,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":35891,"kind":"person","name":"REICIN ALISE","position":1,"cik":"0001757533","reported_name":"REICIN ALISE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2024-06-24T20:12:52.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":289600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The shares subject to the option vest as to 25% of the shares on June 20, 2025 with the remainder vesting in the following 36 equal monthly installments, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":289600,"derivative":{"exercise_price":16.8,"expiration_date":"2034-06-19","underlying":"Common Stock","underlying_shares":289600},"source":{"system":"sec-edgar","filing":"0001415889-24-017952","document":"form4-06242024_080648.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1681087/000141588924017952/form4-06242024_080648.xml","form_type":"4"}},{"id":1470280,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":35891,"kind":"person","name":"REICIN ALISE","position":1,"cik":"0001757533","reported_name":"REICIN ALISE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2024-06-24T20:12:52.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":23380,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Upon the closing of the Merger, each outstanding option to purchase shares of Tectonic common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tectonic stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split."},{"field":"shares","element":"transactionShares","label":"F5","text":"Upon the closing of the Merger, each outstanding option to purchase shares of Tectonic common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tectonic stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Upon the closing of the Merger, each outstanding option to purchase shares of Tectonic common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tectonic stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Received in exchange for a stock option to acquire 43,750 shares of Tectonic common stock pursuant to the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The shares subject to the option vest in 42 equal monthly installments beginning on July 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F5","text":"Upon the closing of the Merger, each outstanding option to purchase shares of Tectonic common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tectonic stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split."}],"balance_after":23380,"derivative":{"exercise_price":5.38,"expiration_date":"2033-11-30","underlying":"Common Stock","underlying_shares":23380},"source":{"system":"sec-edgar","filing":"0001415889-24-017952","document":"form4-06242024_080648.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1681087/000141588924017952/form4-06242024_080648.xml","form_type":"4"}},{"id":1470279,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":35891,"kind":"person","name":"REICIN ALISE","position":1,"cik":"0001757533","reported_name":"REICIN ALISE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2024-06-24T20:12:52.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":33923,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Upon the closing of the Merger, each outstanding option to purchase shares of Tectonic common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tectonic stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split."},{"field":"shares","element":"transactionShares","label":"F5","text":"Upon the closing of the Merger, each outstanding option to purchase shares of Tectonic common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tectonic stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Upon the closing of the Merger, each outstanding option to purchase shares of Tectonic common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tectonic stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Received in exchange for a stock option to acquire 63,478 shares of Tectonic common stock pursuant to the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares subject to the option vest as follows: (i) 4,079 shares on June 30, 2024; (ii) 4,078 shares on July 31, 2024, (iii) 4,078 shares on August 31, 2024, (iv) 4,079 shares on September 30, 2024, (v) 4,078 shares on October 31, 2024, (vi) 1,297 shares on November 30, 2024, (vii) 4,078 shares on January 31, 2025, (viii) 4,078 shares on February 28, 2025 and (iv) 4,078 shares on March 31, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F5","text":"Upon the closing of the Merger, each outstanding option to purchase shares of Tectonic common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tectonic stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split."}],"balance_after":33923,"derivative":{"exercise_price":2.38,"expiration_date":"2031-06-27","underlying":"Common Stock","underlying_shares":33923},"source":{"system":"sec-edgar","filing":"0001415889-24-017952","document":"form4-06242024_080648.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1681087/000141588924017952/form4-06242024_080648.xml","form_type":"4"}},{"id":1470278,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":35891,"kind":"person","name":"REICIN ALISE","position":1,"cik":"0001757533","reported_name":"REICIN ALISE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-06-24T20:12:52.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":124530,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Received in exchange for 233,019 shares of common stock of Tectonic on the same terms and conditions as set forth in footnote (2) herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held by the Reicin-Boiarsky Family Trust (the \"Trust\"). The Reporting Person's spouse is a co-trustee of the Trust. Accordingly, the Reporting Person may be deemed to have shared voting and dispositive power over the securities held by the Trust. The Reporting Person disclaims beneficial ownership of the shares held by the Trust except to the extent of her pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose."}],"balance_after":124530,"source":{"system":"sec-edgar","filing":"0001415889-24-017952","document":"form4-06242024_080648.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1681087/000141588924017952/form4-06242024_080648.xml","form_type":"4"}},{"id":1470277,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":35891,"kind":"person","name":"REICIN ALISE","position":1,"cik":"0001757533","reported_name":"REICIN ALISE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-06-24T20:12:52.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":166580,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Certain of these shares are subject to vesting and a repurchase right in favor of the Issuer, as follows: (i) 2,256 shares on July 10, 2024, (ii) 2,256 shares on August 10, 2024, (iii) 2,781 shares on November 30, 2024, and (iv) 4,079 shares on December 31, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Received in exchange for 311,703 shares of common stock of Tectonic Therapeutic, Inc., a Delaware corporation (\"Tectonic\"), pursuant to an Agreement and Plan of Merger dated as of January 30, 2024 (the \"Merger Agreement\") by and among AVROBIO, Inc., a Delaware corporation (\"AVROBIO\"), Tectonic and Alpine Merger Subsidiary, Inc., a direct, wholly owned subsidiary of AVROBIO (the \"Merger Sub\"). Under the terms of the Merger Agreement, on June 20, 2024, Merger Sub merged with and into Tectonic (the \"Merger\"), with Tectonic surviving the Merger as a wholly owned subsidiary of AVROBIO. Upon the closing of the Merger, each share of Tectonic common stock was converted into the right to receive 0.534419990 shares of the Issuer's common stock, after giving effect to a reverse stock split of the Issuer's common stock of 1-for-12. Subsequent to the Merger, the name of the Issuer was changed from AVROBIO, Inc. to Tectonic Therapeutic, Inc."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Certain of these shares are subject to vesting and a repurchase right in favor of the Issuer, as follows: (i) 2,256 shares on July 10, 2024, (ii) 2,256 shares on August 10, 2024, (iii) 2,781 shares on November 30, 2024, and (iv) 4,079 shares on December 31, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date."}],"balance_after":166580,"source":{"system":"sec-edgar","filing":"0001415889-24-017952","document":"form4-06242024_080648.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681087/000141588924017952/form4-06242024_080648.xml","form_type":"4"}},{"id":1486036,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":35891,"kind":"person","name":"REICIN ALISE","position":1,"cik":"0001757533","reported_name":"REICIN ALISE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-07T20:22:01.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":54278,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2025 and (ii) immediately prior to the 2025 annual meeting of stockholders of Sana Biotechnology, Inc. (\"Sana\"), provided that the reporting person provides continuous service to Sana through such date."}],"balance_after":54278,"derivative":{"exercise_price":7.36,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":54278},"source":{"system":"sec-edgar","filing":"0001562180-24-004841","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1757533/000156218024004841/primarydocument.xml","form_type":"4"}},{"id":1853772,"issuer":{"id":5594,"kind":"organization","name":"Q32 Bio Inc.","symbol":"QTTB"},"owners":[{"id":35891,"kind":"person","name":"REICIN ALISE","position":1,"cik":"0001757533","reported_name":"REICIN ALISE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (Right to Buy)","published_at":"2023-06-15T22:04:26.000Z","date":"2023-06-14","kind":"grant","planned":false,"acquired":true,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable on the earlier of June 14, 2024 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Board as a Non-Employee Director through such vesting date."}],"balance_after":23000,"derivative":{"exercise_price":1.03,"expiration_date":"2033-06-14","underlying":"Common Stock","underlying_shares":23000},"source":{"system":"sec-edgar","filing":"0000950170-23-028379","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1661998/000095017023028379/ownership.xml","form_type":"4"}},{"id":1859961,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":35891,"kind":"person","name":"REICIN ALISE","position":1,"cik":"0001757533","reported_name":"REICIN ALISE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-09T20:34:19.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 8, 2024 and (ii) immediately prior to Sana Biotechnology, Inc.'s next annual meeting of stockholders following June 8, 2023."}],"balance_after":65000,"derivative":{"exercise_price":6.7,"expiration_date":"2033-06-07","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001562180-23-005031","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1757533/000156218023005031/primarydocument.xml","form_type":"4"}},{"id":2226533,"issuer":{"id":5594,"kind":"organization","name":"Q32 Bio Inc.","symbol":"QTTB"},"owners":[{"id":35891,"kind":"person","name":"REICIN ALISE","position":1,"cik":"0001757533","reported_name":"REICIN ALISE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (Right to Buy)","published_at":"2022-06-17T20:05:31.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable on the earlier of June 15, 2023 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Board as a Non-Employee Director through such vesting date."}],"balance_after":18000,"derivative":{"exercise_price":1.88,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0000899243-22-023064","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1661998/000089924322023064/doc4.xml","form_type":"4"}},{"id":2238620,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":35891,"kind":"person","name":"REICIN ALISE","position":1,"cik":"0001757533","reported_name":"REICIN ALISE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-08T22:39:18.000Z","date":"2022-06-06","kind":"grant","acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2023 and (ii) immediately prior to Sana Biotechnology, Inc.'s next annual meeting of stockholders following June 6, 2022."}],"balance_after":65000,"derivative":{"exercise_price":4.95,"expiration_date":"2032-06-05","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001562180-22-004946","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1757533/000156218022004946/primarydocument.xml","form_type":"4"}},{"id":2658217,"issuer":{"id":5594,"kind":"organization","name":"Q32 Bio Inc.","symbol":"QTTB"},"owners":[{"id":35891,"kind":"person","name":"REICIN ALISE","position":1,"cik":"0001757533","reported_name":"REICIN ALISE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (Right to Buy)","published_at":"2021-06-22T21:40:12.000Z","date":"2021-06-17","kind":"grant","acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable on the earlier of June 17, 2022 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Board as a Non-Employee Director through such vesting date."}],"balance_after":18000,"derivative":{"exercise_price":7.26,"expiration_date":"2031-06-17","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0000899243-21-025331","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1661998/000089924321025331/doc4.xml","form_type":"4"}},{"id":2848636,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":35891,"kind":"person","name":"REICIN ALISE","position":1,"cik":"0001757533","reported_name":"REICIN ALISE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-18T23:59:59.000Z","date":"2021-02-03","kind":"grant","acquired":true,"shares":11795,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4/A is being filed to correct a calculation error in regards to the number of option shares acquired."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option shall vest and become exercisable in full on February 3, 2022."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"This Form 4/A is being filed to correct a calculation error in regards to the number of option shares acquired."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This Form 4/A is being filed to correct a calculation error in regards to the number of option shares acquired."}],"balance_after":11795,"derivative":{"exercise_price":25,"expiration_date":"2031-02-02","underlying":"Common Stock","underlying_shares":11795},"source":{"system":"sec-edgar","filing":"0000899243-21-007195","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1757533/000089924321007195/doc4a.xml","form_type":"4/A","original_submission_date":"2021-02-05"}},{"id":2876243,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":35891,"kind":"person","name":"REICIN ALISE","position":1,"cik":"0001757533","reported_name":"REICIN ALISE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-05T22:15:07.000Z","date":"2021-02-03","kind":"grant","acquired":true,"shares":7000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option shall vest and become exercisable in full on February 3, 2022."}],"balance_after":7000,"derivative":{"exercise_price":25,"expiration_date":"2031-02-02","underlying":"Common Stock","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0000899243-21-005067","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1757533/000089924321005067/doc4.xml","form_type":"4"}},{"id":3111402,"issuer":{"id":5594,"kind":"organization","name":"Q32 Bio Inc.","symbol":"QTTB"},"owners":[{"id":35891,"kind":"person","name":"REICIN ALISE","position":1,"cik":"0001757533","reported_name":"REICIN ALISE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (Right to Buy)","published_at":"2020-06-12T21:33:50.000Z","date":"2020-06-10","kind":"grant","acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable on the earlier of June 10, 2021 or the day immediately prior to the date of the next annual meeting of the Company's stockholders occurring after the date of grant, in either case subject to the Non-Employee Director continuing in service on the Board as a Non-Employee Director through such vesting date."}],"balance_after":18000,"derivative":{"exercise_price":16.32,"expiration_date":"2030-06-10","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0000899243-20-016398","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1661998/000089924320016398/doc4.xml","form_type":"4"}},{"id":3362062,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":35891,"kind":"person","name":"REICIN ALISE","position":1,"cik":"0001757533","reported_name":"REICIN ALISE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLOBAL CLINICAL DEV."}}],"security":"Restricted Stock Unit","published_at":"2019-11-22T07:31:03.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":37660,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each restricted stock unit represents a contingent right to receive one share of Celgene common stock."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":37660},"source":{"system":"sec-edgar","filing":"0001415889-19-001372","document":"form4-11222019_071151.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001372/form4-11222019_071151.xml","form_type":"4"}},{"id":3362061,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":35891,"kind":"person","name":"REICIN ALISE","position":1,"cik":"0001757533","reported_name":"REICIN ALISE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLOBAL CLINICAL DEV."}}],"security":"Restricted Stock Unit","published_at":"2019-11-22T07:31:03.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":23807,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each restricted stock unit represents a contingent right to receive one share of Celgene common stock."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":23807},"source":{"system":"sec-edgar","filing":"0001415889-19-001372","document":"form4-11222019_071151.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001372/form4-11222019_071151.xml","form_type":"4"}},{"id":3362060,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":35891,"kind":"person","name":"REICIN ALISE","position":1,"cik":"0001757533","reported_name":"REICIN ALISE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLOBAL CLINICAL DEV."}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:03.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":42500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option was fully exercisable"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":75.61,"expiration_date":"2028-11-01","underlying":"Common Stock","underlying_shares":42500},"source":{"system":"sec-edgar","filing":"0001415889-19-001372","document":"form4-11222019_071151.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001372/form4-11222019_071151.xml","form_type":"4"}},{"id":3362059,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":35891,"kind":"person","name":"REICIN ALISE","position":1,"cik":"0001757533","reported_name":"REICIN ALISE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLOBAL CLINICAL DEV."}}],"security":"Common Stock","published_at":"2019-11-22T07:31:03.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":44615,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects disposition in connection with the Merger Agreement.  Upon the Effective Time, each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one CVR issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-19-001372","document":"form4-11222019_071151.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001372/form4-11222019_071151.xml","form_type":"4"}},{"id":3362058,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":35891,"kind":"person","name":"REICIN ALISE","position":1,"cik":"0001757533","reported_name":"REICIN ALISE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLOBAL CLINICAL DEV."}}],"security":"Common Stock","published_at":"2019-11-22T07:31:03.000Z","date":"2019-11-20","kind":"grant","acquired":true,"shares":24209,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of Celgene common stock acquired in connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS.  These shares were deemed acquired upon satisfaction of performance criteria applicable to Celgene performance-based restricted stock units at the effective time of such merger (the \"Effective Time\").  In accordance with the Merger Agreement, these performance-based restricted stock units were assumed by BMS and converted into service-based restricted stock units relating to BMS common stock and contingent value rights (\"CVRs\") in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":44615,"source":{"system":"sec-edgar","filing":"0001415889-19-001372","document":"form4-11222019_071151.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001372/form4-11222019_071151.xml","form_type":"4"}},{"id":3362057,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":35891,"kind":"person","name":"REICIN ALISE","position":1,"cik":"0001757533","reported_name":"REICIN ALISE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLOBAL CLINICAL DEV."}}],"security":"Common Stock","published_at":"2019-11-22T07:31:03.000Z","date":"2019-11-20","kind":"grant","acquired":true,"shares":8927,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of Celgene common stock acquired in connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS.  These shares were deemed acquired upon satisfaction of performance criteria applicable to Celgene performance-based restricted stock units at the effective time of such merger (the \"Effective Time\").  In accordance with the Merger Agreement, these performance-based restricted stock units were assumed by BMS and converted into service-based restricted stock units relating to BMS common stock and contingent value rights (\"CVRs\") in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":20406,"source":{"system":"sec-edgar","filing":"0001415889-19-001372","document":"form4-11222019_071151.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001372/form4-11222019_071151.xml","form_type":"4"}},{"id":3362056,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":35891,"kind":"person","name":"REICIN ALISE","position":1,"cik":"0001757533","reported_name":"REICIN ALISE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLOBAL CLINICAL DEV."}}],"security":"Common Stock","published_at":"2019-11-22T07:31:03.000Z","date":"2019-11-20","kind":"grant","acquired":true,"shares":4298,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of Celgene common stock acquired in connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS.  These shares were deemed acquired upon satisfaction of performance criteria applicable to Celgene performance-based restricted stock units at the effective time of such merger (the \"Effective Time\").  In accordance with the Merger Agreement, these performance-based restricted stock units were assumed by BMS and converted into service-based restricted stock units relating to BMS common stock and contingent value rights (\"CVRs\") in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":11479,"source":{"system":"sec-edgar","filing":"0001415889-19-001372","document":"form4-11222019_071151.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001372/form4-11222019_071151.xml","form_type":"4"}},{"id":3382718,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":35891,"kind":"person","name":"REICIN ALISE","position":1,"cik":"0001757533","reported_name":"REICIN ALISE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLOBAL CLINICAL DEV."}}],"security":"Restricted Stock Unit","published_at":"2019-11-04T16:05:32.000Z","date":"2019-11-01","kind":"exercise","acquired":false,"shares":11903,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"One-third of the restricted stock units granted to the reporting person on November 1, 2018 vested and settled for shares of the Company's common stock."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Company's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The restricted stock units were issued pursuant to the Company's 2014 Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the restricted stock units granted to the reporting person on November 1, 2018 vested and settled for shares of the Company's common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"One-third of the restricted stock units granted to the reporting person on November 1, 2018 vested and settled for shares of the Company's common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The remainder of the restricted stock units will vest in two installments as follows: 11,903 shares on November 1,2020 and 11,904 shares on  November 1, 2021. Vested shares will be delivered to the reporting person promptly after the vesting date."}],"balance_after":23807,"derivative":{"underlying":"Common Stock","underlying_shares":11903},"source":{"system":"sec-edgar","filing":"0001415889-19-001258","document":"form4-11042019_041119.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001258/form4-11042019_041119.xml","form_type":"4"}},{"id":3382717,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":35891,"kind":"person","name":"REICIN ALISE","position":1,"cik":"0001757533","reported_name":"REICIN ALISE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLOBAL CLINICAL DEV."}}],"security":"Common Stock","published_at":"2019-11-04T16:05:32.000Z","date":"2019-11-01","kind":"tax_withholding","acquired":false,"shares":4722,"price":108.53,"value":512478.66,"ownership":{"direct":true},"balance_after":7181,"source":{"system":"sec-edgar","filing":"0001415889-19-001258","document":"form4-11042019_041119.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001258/form4-11042019_041119.xml","form_type":"4"}},{"id":3382716,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":35891,"kind":"person","name":"REICIN ALISE","position":1,"cik":"0001757533","reported_name":"REICIN ALISE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLOBAL CLINICAL DEV."}}],"security":"Common Stock","published_at":"2019-11-04T16:05:32.000Z","date":"2019-11-01","kind":"exercise","acquired":true,"shares":11903,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"One-third of the restricted stock units granted to the reporting person on November 1, 2018 vested and settled for shares of the Company's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Company's common stock."}],"balance_after":11903,"source":{"system":"sec-edgar","filing":"0001415889-19-001258","document":"form4-11042019_041119.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001258/form4-11042019_041119.xml","form_type":"4"}},{"id":3461721,"issuer":{"id":5594,"kind":"organization","name":"Q32 Bio Inc.","symbol":"QTTB"},"owners":[{"id":35891,"kind":"person","name":"REICIN ALISE","position":1,"cik":"0001757533","reported_name":"REICIN ALISE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (Right to Buy)","published_at":"2019-07-15T21:36:20.000Z","date":"2019-07-11","kind":"grant","acquired":true,"shares":31160,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in three substantially equal annual installments following the date of grant, subject to the Non-Employee Director continuing service on the Board as a Non-Employee Director through each such vesting date."}],"balance_after":31160,"derivative":{"exercise_price":19.25,"expiration_date":"2029-07-11","underlying":"Common Stock","underlying_shares":31160},"source":{"system":"sec-edgar","filing":"0000899243-19-019625","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1661998/000089924319019625/doc4.xml","form_type":"4"}},{"id":3616284,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":35891,"kind":"person","name":"REICIN ALISE","position":1,"cik":"0001757533","reported_name":"REICIN ALISE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLOBAL CLINICAL DEV."}}],"security":"Restricted Stock Unit","published_at":"2019-03-05T16:05:28.000Z","date":"2019-03-01","kind":"grant","acquired":true,"shares":37660,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Company's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units will vest in three equal annual installments, beginning on March 1, 2020.  Vested shares will be delivered to the reporting person promptly after the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units will vest in three equal annual installments, beginning on March 1, 2020.  Vested shares will be delivered to the reporting person promptly after the vesting date."}],"balance_after":37660,"derivative":{"underlying":"Common Stock","underlying_shares":37660},"source":{"system":"sec-edgar","filing":"0001415889-19-000250","document":"form4-03052019_040316.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919000250/form4-03052019_040316.xml","form_type":"4"}},{"id":3777467,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":35891,"kind":"person","name":"REICIN ALISE","position":1,"cik":"0001757533","reported_name":"REICIN ALISE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLOBAL CLINICAL DEV."}}],"security":"Restricted Stock Unit","published_at":"2018-11-02T16:15:18.000Z","date":"2018-11-01","kind":"grant","acquired":true,"shares":35710,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the Company's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The restricted stock units were issued pursuant to the Company's 2014 Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units will vest in three equal annual installments commencing on November 1, 2019. Vested shares will be delivered to the reporting person promptly after the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units will vest in three equal annual installments commencing on November 1, 2019. Vested shares will be delivered to the reporting person promptly after the vesting date."}],"balance_after":35710,"derivative":{"underlying":"Common Stock","underlying_shares":35710},"source":{"system":"sec-edgar","filing":"0001415889-18-001581","document":"form4-11022018_041101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588918001581/form4-11022018_041101.xml","form_type":"4"}},{"id":3777466,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":35891,"kind":"person","name":"REICIN ALISE","position":1,"cik":"0001757533","reported_name":"REICIN ALISE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLOBAL CLINICAL DEV."}}],"security":"Stock Option (right to buy)","published_at":"2018-11-02T16:15:18.000Z","date":"2018-11-01","kind":"grant","acquired":true,"shares":42500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The option was issued pursuant to the Company's 2014 Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option is immediately exercisable and will vest in four equal annual installments commencing on November 1, 2019."}],"balance_after":42500,"derivative":{"exercise_price":75.61,"expiration_date":"2028-11-01","underlying":"Common Stock","underlying_shares":42500},"source":{"system":"sec-edgar","filing":"0001415889-18-001581","document":"form4-11022018_041101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588918001581/form4-11022018_041101.xml","form_type":"4"}}]}